AZD0156: Selective ATM Kinase Inhibitor for Cancer Research

Principle and Setup: Harnessing ATM Inhibition in Cancer Models

ATM kinase is pivotal in the DNA damage response, governing DNA double-strand break repair, checkpoint control, and genomic stability. AZD0156 (CAS 1821428-35-6) is a potent, orally bioavailable small-molecule ATM kinase inhibitor, exhibiting over 1000-fold selectivity against other PIKK family kinases. This specificity enables researchers to interrogate ATM-dependent signaling with minimal off-target effects, making AZD0156 the preferred selective ATM inhibitor for cancer research, particularly in studies of DNA damage response and metabolic adaptation.

Recent studies, such as the work by Huang et al. (J Cell Biol, 2023), demonstrate that ATM inhibition not only disrupts canonical DNA repair but also drives metabolic reprogramming via increased macropinocytosis—a nutrient scavenging mechanism exploited by tumor cells under stress. This dual impact uniquely positions AZD0156 as a tool for uncovering new therapeutic vulnerabilities beyond DNA repair.

• Chemical Profile: C₂₆H₃₁N₅O₃, MW 461.56 g/mol
• Solubility: ≥23.1 mg/mL in DMSO (with gentle warming), ≥5.49 mg/mL in ethanol, insoluble in water
• Quality: Supplied at ≥98% purity (HPLC, NMR)
• Storage: -20°C; use solutions promptly for maximal activity

Step-by-Step Experimental Workflow with AZD0156

1. Compound Preparation

• Weigh desired amount of AZD0156 using an analytical balance (calculate based on required final concentration and experimental scale).
• Dissolve in DMSO at concentrations up to 23.1 mg/mL; heat gently (<40°C) to facilitate dissolution.
• Aliquot stock solutions; avoid repeated freeze-thaw cycles. For best results, use aliquots within one week.

2. In Vitro ATM Inhibition Assays

• Seed cancer cell lines (e.g., ovarian, lung, or colorectal) in appropriate culture conditions.
• Treat cells with AZD0156 at concentrations ranging from 10–500 nM, depending on cell type sensitivity and desired endpoint. For combination studies, add DNA-damaging agents (e.g., doxorubicin, etoposide) concurrently or sequentially.
• Monitor ATM signaling by immunoblot (e.g., phospho-ATM, γH2AX), cell viability (MTT/XTT assays), and checkpoint markers.
• For metabolic adaptation studies, assess macropinocytosis using fluorescent dextran uptake, as outlined in Huang et al.

3. In Vivo Applications

• Administer AZD0156 orally to mouse xenograft models at dosages informed by prior preclinical pharmacokinetic studies (e.g., 10–50 mg/kg daily).
• Assess tumor growth inhibition, DNA damage response markers, and metabolic phenotypes (e.g., BCAA levels in tumor microenvironment).

4. Protocol Enhancements

• For maximal impact in cancer therapy research, combine AZD0156 with DNA double-strand break-inducing agents or inhibitors of macropinocytosis (e.g., EIPA) to probe synthetic lethality and metabolic vulnerabilities.
• Use synchronized cell populations for checkpoint control modulation studies.
• Incorporate quantitative metabolomics (e.g., LC-MS/MS) to track metabolic fluxes post-ATM inhibition.

Advanced Applications and Comparative Advantages

1. Dissecting DNA Double-Strand Break Repair

AZD0156 allows for high-fidelity interruption of ATM-driven repair pathways, enabling precise mapping of DNA repair dependencies. In preclinical models, AZD0156 amplifies the cytotoxicity of radiotherapy and chemotherapeutics that induce DNA breaks, underscoring its value in cancer therapy research.

2. Exposing Metabolic Vulnerabilities

As shown by Huang et al., ATM inhibition with AZD0156 induces macropinocytosis and enhances amino acid uptake—particularly BCAAs—creating novel points of metabolic fragility. This effect is most pronounced under nutrient deprivation, mimicking the tumor microenvironment (TME). Inhibition of both ATM and macropinocytosis synergistically suppresses tumor proliferation and viability, highlighting a rational combination strategy for future translational studies.

3. Comparative Insights

Compared with other PIKK family kinase inhibitors, AZD0156's >1000-fold selectivity minimizes confounding effects on related pathways such as DNA-PK or mTOR, allowing for unambiguous dissection of ATM-specific biology. This differentiates it from less selective inhibitors, as discussed in the article "AZD0156 and the New Paradigm of ATM Kinase Inhibition", which extends the mechanistic rationale for integrating DNA damage response disruption with metabolic adaptation in cancer cells.

Furthermore, as detailed in "AZD0156 and ATM Inhibition: Unveiling Metabolic Vulnerabilities", the unique ability of AZD0156 to trigger metabolic adaptation provides a strategic advantage for designing combination treatments that exploit the metabolic plasticity of resistant tumor cells. This complements findings from "AZD0156: Potent ATM Kinase Inhibitor for Cancer Research", which offers actionable protocols and troubleshooting tips to maximize data quality in metabolic and DNA repair assays.

Troubleshooting and Optimization Tips

• Solubility Issues: If AZD0156 does not dissolve at expected concentrations in DMSO, gently warm the solution (≤40°C) and vortex thoroughly. Avoid extended heating to prevent degradation.
• Cellular Toxicity: High DMSO concentrations (>0.1%) may confound cell viability results. Prepare working solutions to ensure final DMSO is ≤0.1% in cell culture.
• Variable Response: Tumor cell lines with defective p53 or altered c-MYC may exhibit divergent metabolic responses to ATM inhibition (see Huang et al., 2023). Validate findings across multiple genetic backgrounds for robust conclusions.
• Checkpoint Analysis: For checkpoint control modulation, time-course studies post-treatment (e.g., 0, 2, 6, 24 hours) improve resolution of dynamic signaling events.
• Combination Treatments: Sequence addition of AZD0156 and DNA-damaging agents to mimic clinical regimens and optimize synergy.
• Storage: Avoid long-term storage of AZD0156 solutions; use freshly prepared aliquots to maintain inhibitor potency.

Future Outlook: Translational Opportunities and Next Steps

AZD0156 is currently under early clinical evaluation for advanced cancer, with ongoing studies poised to define optimal dosing and combination strategies. The emerging insight that ATM inhibition stimulates protumorigenic nutrient uptake via macropinocytosis (see Huang et al., 2023) suggests novel avenues for metabolic co-targeting—particularly in tumors with high macropinocytic activity or BCAA dependence.

As highlighted in "AZD0156: Unraveling ATM Inhibition and Metabolic Adaptation", the integration of metabolic profiling, DNA repair assays, and functional genomics will further refine the application of ATM kinase inhibitors in precision oncology. The combination of AZD0156 with targeted metabolic inhibitors or immunomodulatory agents represents an exciting frontier for next-generation cancer therapy research.

Key Takeaway: By leveraging the potent and selective properties of AZD0156, researchers can dissect ATM-dependent DNA repair and metabolic adaptation with unprecedented clarity, accelerating the discovery of actionable vulnerabilities in cancer cells and informing strategic therapeutic development.